Pramlintide vs Semaglutide
A side-by-side research comparison of Pramlintide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pramlintide | Semaglutide |
|---|---|---|
| Full name | Pramlintide (Symlin) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | FDA Approved |
| Mechanism | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 3949.4 Da | 4,114 Da |
| Half-life | ~48 minutes | 7 days (168 hours) |
| Bioavailability | Subcutaneous injection | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 15-120 mcg before meals | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Before major meals | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.